

Supplementary Figure 1. Treatment response in groups classified by dose and comparison of outcomes between CLAG and FLAG regimens. (A) No difference of CR was found among low dose cytarabine group, intermediate cytarabine group and high cytarabine group; (B) No difference of CR was observed between CLAG group and FLAG group; (C) No difference of OS was found among low dose cytarabine group, intermediate cytarabine group and high cytarabine group; (D) No difference of OS was observed between CLAG group and FLAG group. Comparison among groups were performed with Chi-squared test and log-rank test. $\mathrm{P}<0.05$ was considered significant.


Supplementary Figure 2. Treatment outcomes in groups classified by age. (A) CR in patients with age $>=60$ years was reduced compared to patients with age $<60$ years; (B) OS in patients with age $>=60$ years was decreased compared to patients with age $<60$ years; (C) No difference of rate in high dose cytarabine, intermediate dose cytarabine and low dose cytarabine was observed between patients with age $>=60$ years and patients with age $<60$ years. Comparison between groups were performed with Chi-squared test, log-rank test and Wilcoxon rank sum test. $\mathrm{P}<0.05$ was considered significant.

Supplementary Table 1. Adverse events

| Items | $\begin{aligned} & \text { FLAG } \\ & (\mathrm{n}=46) \end{aligned}$ | $\begin{aligned} & \text { CAG/DAG } \\ & (\mathrm{n}=30) \end{aligned}$ | $\begin{aligned} & \text { CLAG } \\ & (\mathrm{n}=27) \end{aligned}$ | $\begin{aligned} & \text { MEA } \\ & (\mathrm{n}=17) \end{aligned}$ | IA/DA/MA $(\mathrm{n}=12)$ | $\begin{aligned} & \text { HAA/HAD } \\ & (\mathrm{n}=10) \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Febrile neutropenia ( $\mathrm{n} / \%$ ) | 41 (89.1) | 25 (83.3) | 23 (85.2) | 14 (82.4) | 10 (83.3) | 8 (80.0) |
| Thrombocytopenia (n/\%) | 40 (87.0) | 26 (86.7) | 21 (77.8) | 11 (64.7) | 8 (66.7) | 7 (70.0) |
| Infection ( $\mathrm{n} / \%$ ) | 31 (67.4) | 19 (63.3) | 18 (66.7) | 5 (29.4) | 4 (33.3) | 6 (60.0) |
| Hemorrhage ( $\mathrm{n} / \%$ ) | 22 (46.8) | 4 (13.3) | 8 (29.6) | 5 (29.4) | 2 (16.7) | 3 (30.0) |
| ALT or AST elevation (n/\%) | 6 (13.0) | 2 (6.7) | 2 (7.4) | 4 (23.5) | 0 (0.0) | 0 (0.0) |
| Cardiotoxicity ( $\mathrm{n} / \%$ ) | 2 (4.3) | 0 (0.0) | 1 (3.7) | 1 (5.9) | 1 (8.3) | 1 (10.0) |
| Nausea/vomiting ( $\mathrm{n} / \%$ ) | 16 (34.8) | 7 (23.3) | 13 (48.1) | 2 (11.7) | 1 (8.3) | 4 (40.0) |
| Others (n/\%) | 5 (10.9) | 2 (6.7) | 4 (14.8) | 2 (11.7) | 2 (16.7) | 2 (20.0) |

Date were presented as count (\%). ALT = alanine aminotransferase, $\mathrm{AST}=$ aspartate aminotransferase.

